PTC Therapeutics (PTCT)
(Real Time Quote from BATS)
$33.55 USD
-0.61 (-1.79%)
Updated May 2, 2024 10:56 AM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
PTC Therapeutics (PTCT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$29.67 | $45.00 | $16.00 | -13.14% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for PTC Therapeutics comes to $29.67. The forecasts range from a low of $16.00 to a high of $45.00. The average price target represents a decline of 13.14% from the last closing price of $34.16.
Analyst Price Targets (12)
Broker Rating
PTC Therapeutics currently has an average brokerage recommendation (ABR) of 2.79 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 2.84 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, five are Strong Buy, representing 35.71% of all recommendations. A month ago, Strong Buy represented 35.71%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 4 | 4 | 4 | 5 |
Sell | 1 | 2 | 2 | 2 | 2 |
Strong Sell | 3 | 3 | 3 | 3 | 3 |
ABR | 2.79 | 2.84 | 2.84 | 2.84 | 2.85 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/25/2024 | William Blair | Sami Corwin | Strong Buy | Strong Buy |
3/1/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
2/29/2024 | Raymond James | Danielle Brill | Strong Sell | Strong Sell |
1/15/2024 | SVB Securities | Joseph P Schwartz | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.79 |
ABR (Last week) | 2.84 |
# of Recs in ABR | 14 |
Average Target Price | $29.67 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 252 |
Current Quarter EPS Est: | -1.23 |